After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available nationwide in the next few months.
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for ...
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...